Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) and Amicus Therapeutics (NASDAQ:FOLD – Get Free Report) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.
Risk & Volatility
Protagonist Therapeutics has a beta of 2.34, indicating that its share price is 134% more volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.
Insider & Institutional Ownership
98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.4% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 2.2% of Amicus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Protagonist Therapeutics | 52.76% | 34.68% | 30.98% |
| Amicus Therapeutics | -10.62% | 12.44% | 2.60% |
Valuation and Earnings
This table compares Protagonist Therapeutics and Amicus Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Protagonist Therapeutics | $434.43 million | 5.42 | -$78.96 million | $4.20 | 9.13 |
| Amicus Therapeutics | $528.30 million | 5.15 | -$151.58 million | ($0.18) | -49.22 |
Protagonist Therapeutics has higher earnings, but lower revenue than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current recommendations and price targets for Protagonist Therapeutics and Amicus Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Protagonist Therapeutics | 0 | 1 | 7 | 1 | 3.00 |
| Amicus Therapeutics | 0 | 2 | 7 | 0 | 2.78 |
Protagonist Therapeutics presently has a consensus price target of $55.89, suggesting a potential upside of 45.73%. Amicus Therapeutics has a consensus price target of $16.75, suggesting a potential upside of 89.05%. Given Amicus Therapeutics’ higher probable upside, analysts clearly believe Amicus Therapeutics is more favorable than Protagonist Therapeutics.
Summary
Protagonist Therapeutics beats Amicus Therapeutics on 12 of the 14 factors compared between the two stocks.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
About Amicus Therapeutics
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
